Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Medical Detox Center Analyzes Risks of Rising Prescription Drug Prices and Appeals for Affordability
  • USA - English


News provided by

JoTo PR

Mar 14, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Kent Runyon of Novus Medical Detox addresses the increase in the cost of prescription drugs.
Kent Runyon of Novus Medical Detox addresses the increase in the cost of prescription drugs.
Youtube
Youtube

NEW PORT RICHEY, Fla. (PRWEB) March 14, 2016 -- Substantial increases in prescription drug costs have triggered Congressional inquiries and debate within the past few months (1), and two new studies have documented the severity of the price hikes in recent years (2, 3). Novus Medical Detox Center, a leading Florida-based drug treatment facility, warns that this trend is putting patients’ lives at risk and urges pharmaceutical manufacturers to ensure that naloxone and other life-saving drugs remain affordable.

My hope is that the pharmaceutical industry will find a way to balance profitability with a compassionate approach toward the patients who rely on their medications for survival.

Post this

In December 2015, U.S. senators launched a bipartisan investigation into the “egregious price increases” of off-patent drugs, which drew national scrutiny when Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 per pill (1). However, off-patent drugs aren’t the only medications that have become more costly.

Truveris published its annual OneRx National Drug Index report in January 2016 and found that the average cost of prescription drugs rose 10.43% from 2014 to 2015, following a 10.91% increase the previous year (2). Meanwhile, the AARP Rx Price Watch Report released in February revealed that the average annual cost of widely used prescription drugs more than doubled between 2006 and 2013—from $5,571 to $11,341—far outpacing the annual rate of inflation (3).

“There’s no disputing the fact that pharmaceutical companies need to cover research, development, clinical testing, ingredients and other costs involved manufacturing prescription medications. However, hefty annual price increases for drugs that have been on the market for years are putting a strain on the healthcare system and, in some cases, putting patients’ lives in jeopardy,” explained Kent Runyon, Vice President of Community Relations and Chief Strategy and Compliance Officer for Novus Medical Detox Center.

Novus, which provides medically supervised addiction and detox programs, is particularly concerned about the rising cost of drugs like naloxone, which is intended to prevent overdose deaths by blocking the effects of opioids and reversing respiratory depression.

An NPR story reported that injectable naloxone was priced at around $1 per shot a decade ago, but the price has jumped sharply as demand for the drug—particularly its intranasally administered form—has risen. In February 2015, the Baltimore Department of Health was paying $20 per dose of naloxone; but by July 2015, the drug was priced at nearly $40 per dose (4).

While many cities have undertaken efforts to provide naloxone and relevant training to police, emergency responders, and the family and friends of individuals with substance use disorders, Runyon fears that naloxone’s steep price increase will reduce access to the drug and may lead to an increase in overdose deaths.

“If first responders can no longer afford to keep a supply of naloxone with all units, the progress made toward reducing overdose deaths may be undone,” cautioned Runyon. He also emphasized that rapidly rising prescription drug costs not only affect the people who need those medications, but are contributing to rising health insurance premiums and co-pays for all Americans.

Runyon concluded, “While pharmaceutical companies provide an important service and deserve to make a profit, we implore them to keep affordability and accessibility in mind when pricing their products—both for the good of the patients who need them and for the U.S. healthcare system as a whole. My hope is that the pharmaceutical industry will find a way to balance profitability with a compassionate approach toward the patients who rely on their medications for survival.”

Novus is dedicated to helping individuals overcome substance use disorders through medically supervised alcohol and drug detox programs. The Florida detox facility offers individually customized treatment programs designed to help patients safely and comfortably manage their withdrawal symptoms, and its proven medical protocols include 24-hour access to nursing care and withdrawal specialists. Novus is among the few detoxification facilities with expertise in treating high-dose methadone cases, and is proficient in treating other high-dose opioid cases just as effectively.

For more information on Novus Medical Detox Center and its drug treatment programs, visit http://www.novusdetox.com.

About Novus Medical Detox Center:
Novus Medical Detox Center is a Joint Commission Accredited inpatient medical detox facility. Novus offers safe, effective alcohol and drug treatment programs in a home-like residential setting. Located on 3.25 tree-lined acres in New Port Richey, Florida, Novus is licensed by the Florida Department of Children and Families and is known for minimizing the discomfort of withdrawal from prescription medication, drugs or alcohol by creating a customized detox program for each patient. By incorporating medication, natural supplements and fluid replenishment, Novus tailors the detox process for each patient, putting the dignity and humanity back into drug detoxification. Patients have 24/7 medical supervision, including round-the-clock nursing care and access to a withdrawal specialist, and enjoy comfortable private or shared rooms with a telephone, cable television and high-speed Internet access. Novus’ expansion is tied to their contribution to their industry and their local community, ranking number 48 on the Tampa Bay Business Journal’s 2014 Fast 50 Awards list of the fastest-growing companies in Tampa Bay, and number 3,399 on the 2015 Inc. 500/5000 list of fastest-growing companies in America. For more information, visit http://www.novusdetox.com.

1. Siddons, Andrew. “Senate Committee Scrutinizes High Drug Prices”; Washington Health Policy Week in Review; December 14, 2015. commonwealthfund.org/publications/newsletters/washington-health-policy-in-review/2015/dec/dec-14-2015/senate-committee-scrutinizes-high-drug-prices

2. Truveris. “2015 OneRx NDI Annual Report Shows Drug Prices Jumped More Than 10%”; TruTalk; January 12, 2016. truverisblog.tumblr.com/post/137162581932/2015-onerx-ndi-annual-report-shows-drug-prices

3. AARP. Rx Price Watch Report: Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2006 to 2013; February 2016. aarp.org/content/dam/aarp/ppi/2016-02/RX-Price-Watch-Trends-in-Retail-Prices-Prescription-Drugs-Widely-Used-by-Older-Americans.pdf

4. NPR. “Price Soars for Key Weapon Against Heroin Overdoses”; All Things Considered; October 28, 2015. npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.